Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Low-dose interferon-alpha preconditioning and adoptive cell therapy in patients with metastatic melanoma refractory to standard (immune) therapies: a phase I/II study.
Verdegaal E, van der Kooij MK, Visser M, van der Minne C, de Bruin L, Meij P, Terwisscha van Scheltinga A, Welters MJ, Santegoets S, de Miranda N, Roozen I, Liefers GJ, Kapiteijn E, van der Burg SH. Verdegaal E, et al. Among authors: roozen i. J Immunother Cancer. 2020 Mar;8(1):e000166. doi: 10.1136/jitc-2019-000166. J Immunother Cancer. 2020. PMID: 32238469 Free PMC article. Clinical Trial.
Everolimus in Patients With Advanced Follicular-Derived Thyroid Cancer: Results of a Phase II Clinical Trial.
Schneider TC, de Wit D, Links TP, van Erp NP, van der Hoeven JJ, Gelderblom H, Roozen IC, Bos M, Corver WE, van Wezel T, Smit JW, Morreau H, Guchelaar HJ, Kapiteijn E. Schneider TC, et al. Among authors: roozen ic. J Clin Endocrinol Metab. 2017 Feb 1;102(2):698-707. doi: 10.1210/jc.2016-2525. J Clin Endocrinol Metab. 2017. PMID: 27870581 Clinical Trial.
Phase I/II study protocol to assess safety and efficacy of adoptive cell therapy with anti-PD-1 plus low-dose pegylated-interferon-alpha in patients with metastatic melanoma refractory to standard of care treatments: the ACTME trial.
van der Kooij MK, Verdegaal EME, Visser M, de Bruin L, van der Minne CE, Meij PM, Roozen ICFM, Jonker MA, van den Bosch S, Liefers GJ, Speetjens FM, van der Burg SH, Kapiteijn E. van der Kooij MK, et al. Among authors: roozen icfm. BMJ Open. 2020 Nov 24;10(11):e044036. doi: 10.1136/bmjopen-2020-044036. BMJ Open. 2020. PMID: 33234662 Free PMC article.
Intradermal vaccination of HPV-16 E6 synthetic peptides conjugated to an optimized Toll-like receptor 2 ligand shows safety and potent T cell immunogenicity in patients with HPV-16 positive (pre-)malignant lesions.
Speetjens FM, Welters MJP, Slingerland M, van Poelgeest MIE, de Vos van Steenwijk PJ, Roozen I, Boekestijn S, Loof NM, Zom GG, Valentijn ARPM, Krebber WJ, Meeuwenoord NJ, Janssen CAH, Melief CJM, van der Marel GA, Filippov DV, van der Burg SH, Gelderblom H, Ossendorp F. Speetjens FM, et al. Among authors: roozen i. J Immunother Cancer. 2022 Oct;10(10):e005016. doi: 10.1136/jitc-2022-005016. J Immunother Cancer. 2022. PMID: 36261215 Free PMC article. Clinical Trial.
Timed adoptive T cell transfer during chemotherapy in patients with recurrent platinum-sensitive epithelial ovarian cancer.
Verdegaal EME, Santegoets SJ, Welters MJP, de Bruin L, Visser M, van der Minne CE, de Kok PM, Loof NM, Boekestijn S, Roozen I, Westra IM, Meij P, Van der Burg SH, Kroep JR. Verdegaal EME, et al. Among authors: roozen i. J Immunother Cancer. 2023 Nov;11(11):e007697. doi: 10.1136/jitc-2023-007697. J Immunother Cancer. 2023. PMID: 37949617 Free PMC article.
Are Retail Customers Ready for Service Robot Assistants?
Roozen I, Raedts M, Yanycheva A. Roozen I, et al. Int J Soc Robot. 2023;15(1):15-25. doi: 10.1007/s12369-022-00949-z. Epub 2022 Nov 22. Int J Soc Robot. 2023. PMID: 36467284 Free PMC article.